Compare Cytokinetics Inc (CYTK) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs SiTime Corporation — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while SiTime Corporation trades at $654.38 (market cap $19.99B). The key difference: SiTime Corporation is far larger — about 2.4× Cytokinetics Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and SiTime Corporation for 18 Days on average.
| CYTK | SITM | |
|---|---|---|
Market Cap | $8.50B | $19.99B |
Volume | 2,395,556 | 339,821 |
Sector | Health | Technology |
52-Week High | $87.26 | $901.60 |
52-Week Low | $54.76 | $252.76 |
Typical Hold Time | 19 Days | 18 Days |
Enterprise Value | $8.60B | $19.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
SiTime Corp (SITM) trades at $665.16, down 6.46% today but maintains strong analyst support with 100% buy ratings and a $751.43 consensus price target. The stock shows bullish technical signals with support at $659 and resistance at $678, while recent quarterly earnings consistently beat expectations. Revenue growth accelerated to 126.5% year-over-year in Q2 2026, driven by AI infrastructure demand and the Renesas acquisition, though current valuation metrics remain elevated with P/S at 37.99.
SITM presents significant growth potential as a precision timing specialist benefiting from AI data center expansion, with projected revenue growth and margin expansion. However, risks include high valuation multiples, insider selling activity, and dependence on sustained AI infrastructure spending. The stock's current pullback may offer entry opportunity given strong fundamental momentum and unanimous Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
